<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03584321</url>
  </required_header>
  <id_info>
    <org_study_id>MS200101_0003</org_study_id>
    <nct_id>NCT03584321</nct_id>
  </id_info>
  <brief_title>Retrospective Study to Estimate the Current Status of Patients With Non-Obstructive coroNary Artery Disease</brief_title>
  <acronym>RESPOND</acronym>
  <official_title>A Multi-center, Retrospective, Registry Study to Estimate the Current Status of Patients With Non-Obstructive coroNary Artery Disease (CAD) Confirmed Via Coronary Angiography (CAG) (RESPOND Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono Co., Ltd., China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will estimate the current status of participants with non-obstructive coronary
      artery disease confirmed via coronary angiography.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 13, 2017</start_date>
  <completion_date type="Actual">July 11, 2018</completion_date>
  <primary_completion_date type="Actual">July 11, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Non-Obstructive Coronary Artery Disease (CAD)</measure>
    <time_frame>Up to 10 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Combined Cardiovascular Risk Factors</measure>
    <time_frame>Up to 10 Months</time_frame>
    <description>Combined cardiovascular risk factors include: body mass index, smoking habit, hypertension, hyperlipidemia diabetes mellitus, lack of exercise, alcohol intake and family history of early onset cardiovascular disease. Percentage of participants with combined cardiovascular risk factors will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Angina Symptoms</measure>
    <time_frame>Up to 10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pathologic Echocardiography Results</measure>
    <time_frame>Up to 10 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Wall thickness in Participants With Obstructive and Non-Obstructive Coronary Artery Disease (CAD)</measure>
    <time_frame>Up to 10 Months</time_frame>
    <description>Mean left ventricular posterior wall thickness (LVPW), interventricular septum (IVS) thickness, other ventricular wall thickness will be assessed for the participants with obstructive and non-obstructive CAD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular End-Diastolic Volume (LVEDV) in Participants With Obstructive and Non-Obstructive Coronary Artery Disease (CAD)</measure>
    <time_frame>Up to 10 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular End Diastolic Diameter (LVEDD) in Participants With Obstructive and Non-Obstructive Coronary Artery Disease (CAD)</measure>
    <time_frame>Up to 10 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Wall Motion in Participants With Obstructive and Non-Obstructive Coronary Artery Disease (CAD)</measure>
    <time_frame>Up to 10 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Early Trans-Mitral Flow (E) and Late Trans-Mitral Flow by Atrial Contraction (A) in Participants with Obstructive and Non-Obstructive Coronary Artery Disease (CAD)</measure>
    <time_frame>Up to 10 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF) in Participants with Obstructive and Non-Obstructive Coronary Artery Disease (CAD)</measure>
    <time_frame>Up to 10 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Receiving Anti-ischemic Drugs</measure>
    <time_frame>Up to 10 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Myocardial Event Prevention</measure>
    <time_frame>Up to 10 Months</time_frame>
    <description>Percentage of participants achieving event prevention by antiplatelet agent, anticoagulants, Î²-blockers, Angiotensin converting enzyme inhibitor (ACEI), Angiotensin receptor blocker (ARB), statin, aldosterone antagonist will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Obstructive and Non-Obstructive Coronary Artery Disease (CAD) Segregated by Age Groups, Genders, Races and Provinces</measure>
    <time_frame>Up to 10 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Coefficient Between Participants With Non-obstructive CAD confirmed by CAG and Clinical Characteristics</measure>
    <time_frame>Up to 10 Months</time_frame>
    <description>Correlation coefficient between the participants with non-obstructive CAD and different clinical characteristics like demographic characteristics, combined cardiovascular risk factors and angina symptoms will be assessed using logistic regression analysis.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1600</enrollment>
  <condition>Non-Obstructive Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Participants with Coronary Artery Disease</arm_group_label>
    <description>Participants with suspected or confirmed coronary artery disease who underwent coronary angiography during 01 Jan 2013 and 31 Dec 2015 will be observed in the study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who were suspected or had confirmed coronary artery disease and who underwent
        coronary angiography between 01 Jan 2013 and 31 Dec 2015 will be observed in the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who had typical or atypical angina symptom before Coronary Angiography
             examination

          -  Underwent CAG between 01 Jan 2013 and 31 Dec 2015

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participant with history of percutaneous coronary intervention or coronary artery
             bypass surgery

          -  Participant with history of myocardial infarction

          -  Participant with history of cardiac transplant or valve surgery

          -  Presenting with Acute myocardial infarction for coronary angiography

          -  CAG showed myocardial bridge and coronary stenosis greater than or equal to 50 percent
             during systole period

          -  Incomplete or missing data in CAG report

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono Co., Ltd, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Please Contact the Merck KGaA Communication Center</name>
      <address>
        <city>Darmstadt</city>
        <zip>64293</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>June 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>October 29, 2018</last_update_submitted>
  <last_update_submitted_qc>October 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Obstructive Coronary Artery Disease</keyword>
  <keyword>Coronary Angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

